Public Employees Retirement Association of Colorado Trims Position in Moderna, Inc. (NASDAQ:MRNA)

Public Employees Retirement Association of Colorado lessened its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 4.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 46,958 shares of the company’s stock after selling 2,009 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Moderna were worth $5,004,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in MRNA. Raymond James Financial Services Advisors Inc. grew its holdings in Moderna by 2.7% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 58,338 shares of the company’s stock valued at $5,802,000 after buying an additional 1,554 shares in the last quarter. Global Retirement Partners LLC boosted its position in shares of Moderna by 11.4% during the 4th quarter. Global Retirement Partners LLC now owns 3,184 shares of the company’s stock valued at $325,000 after acquiring an additional 327 shares during the last quarter. ICICI Prudential Asset Management Co Ltd boosted its position in shares of Moderna by 9.3% during the 4th quarter. ICICI Prudential Asset Management Co Ltd now owns 3,700 shares of the company’s stock valued at $368,000 after acquiring an additional 314 shares during the last quarter. Center For Asset Management LLC bought a new stake in shares of Moderna during the 4th quarter valued at about $490,000. Finally, Claro Advisors LLC boosted its position in shares of Moderna by 146.2% during the 4th quarter. Claro Advisors LLC now owns 5,612 shares of the company’s stock valued at $558,000 after acquiring an additional 3,333 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

MRNA has been the subject of a number of research analyst reports. William Blair reiterated a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. Canaccord Genuity Group boosted their target price on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a research report on Friday, May 3rd. Oppenheimer boosted their target price on Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 12th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Friday, June 28th. Finally, UBS Group boosted their target price on Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Moderna has an average rating of “Hold” and an average target price of $133.88.

Moderna Stock Down 1.0 %

MRNA stock traded down $1.17 during midday trading on Monday, hitting $120.94. The stock had a trading volume of 1,353,444 shares, compared to its average volume of 3,997,588. The firm has a market cap of $46.35 billion, a price-to-earnings ratio of -7.75 and a beta of 1.67. The business has a 50-day moving average of $134.57 and a two-hundred day moving average of $115.08. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The business had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. During the same period in the previous year, the company posted $0.19 earnings per share. The company’s revenue for the quarter was down 91.0% compared to the same quarter last year. As a group, equities research analysts forecast that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $117.80, for a total value of $1,767,000.00. Following the sale, the director now directly owns 2,239,015 shares of the company’s stock, valued at $263,755,967. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO James M. Mock sold 689 shares of the company’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $118.24, for a total transaction of $81,467.36. Following the transaction, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at $859,486.56. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $117.80, for a total value of $1,767,000.00. Following the transaction, the director now directly owns 2,239,015 shares in the company, valued at $263,755,967. The disclosure for this sale can be found here. Over the last three months, insiders have sold 396,239 shares of company stock valued at $55,428,337. 15.70% of the stock is currently owned by corporate insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.